Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Cognitive Impairment, Hypoalbuminemia, High CRP Level and Past History of Gastro-Intestinal Ulcer: 4 Markers of Frailty Which Identify Older Patients with Malignant Hemopathies Who Shouldn't Benefit from Chemotherapy

Stephanie Dubruille, PhD, Cindy Kenis, PhD, Vincent Thibaud, MD, Yves Libert, PhD, Michel Delforge, MD PhD, Lissandra Dal Lago, MD, Myriam Roos, Cindy Borghgraef, PhD, Pepersack Thierry, MD PhD, Hans Wildiers, MD PhD, Dominique Bron, MD PhD

Blood (2018) 132 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2018-99-118085

Published: 2018

Journal Articles

Early Discontinuation of Lenalidomide in Patients with Relapsing or Refractory Multiple Myeloma: Predictive Factors for Stopping in the Real Life

Aureliano Pistone, MD, Marie Maerevoet, MD, Sebastian Wittnebel, MD PhD, Marie Vercruyssen, Chloé Spilleboudt, MD, Sarah Buntinx, MD, Dominique Bron, MD PhD, Nathalie Meuleman, MD PhD

Blood (2016) 128 (22): 4504.

https://doi.org/10.1182/blood.V128.22.4504.4504

Published: 2016

Journal Articles

Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?

Dang Luan, MD, Karen Willard-Gallo, PhD, Soizic Garaud, PhD, Hugues Duvillier, Jean-Nicolas Lodewyckx, Cinzia Solinas, MD, Pushpamali De Silva, Chunyan Gu-Trantien, PhD, Catherine Sibille, MD PhD, Dominique Bron, MD PhD

Blood (2016) 128 (22): 5983.

https://doi.org/10.1182/blood.V128.22.5983.5983

Published: 2016

Journal Articles

Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry

Gregor Verhoef, MD PhD, Marc Andre, MD, Johan Imschoot, MD, Pamela Graas, Dominique Bron, MD PhD

Blood (2016) 128 (22): 5372.

https://doi.org/10.1182/blood.V128.22.5372.5372

Published: 2016

Journal Articles

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Lionel Ades, MD PhD, Xavier Thomas, MD PhD, Agnès Guerci, MD PhD, Arnaud Pigneux, MD, Norbert Vey, Emmanuel Raffoux, MD, Sylvie Castaigne, MD PhD, Olivier Spertini, Dominique Bron, MD PhD, Jean Pierre Marolleau, MD PhD, Gandhi Damaj, MD, Dominique Bordessoule, MD PhD, Julie Lejeune, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 898.

https://doi.org/10.1182/blood.V128.22.898.898

Published: 2016

Journal Articles

Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring

Stephanie Dubruille, PhD, Cindy Kenis, PhD, Yves Libert, PhD, Michel Delforge, MD PhD, Catherine Choffray, Myriam Roos, Aurélie Collard, Nathalie Meuleman, MD PhD, Marie Maerevoet, MD, Darius Razavi, MD PhD, Hans Wildiers, MD PhD, Dominique Bron, MD PhD

Blood (2016) 128 (22): 2353.

https://doi.org/10.1182/blood.V128.22.2353.2353

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

Use of CD 123 Expression on Blasts from AML, ALL and RAEB As Minimal Residual Disease Marker

Leila Mekkaoui, Celine Rassart, Laurence Rozen, Anne Janssens, Dominique Bron, MD PhD, Alina Ferster, MD PhD, Brigitte Cantinieaux, MDPhD

Blood (2015) 126 (23): 5402.

https://doi.org/10.1182/blood.V126.23.5402.5402

Published: 2015

Journal Articles

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

David Cunningham, Pier Luigi Zinzani, MD PhD, Sarit E. Assouline, MDMSc, Krimo Bouabdallah, MD, Dominique Bron, MD PhD, Corinne Haioun, MD PhD, Luigina Mollica, MD FRCPC, PhD, Marius Giurescu, MDPhD, Igor Gorbatchevsky, MD, Manoel Neves, MD, Marta M. Lemos, MD, Julia Grunert, PhD, Florian Hiemeyer, PhD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2015) 126 (23): 3935.

https://doi.org/10.1182/blood.V126.23.3935.3935

Published: 2015

Journal Articles

Long-Term Overall and Event-Free Survival after RIC Allogeneic Transplantation in Acute Leukemias in a Single Centre - Impact of Age and Donor Type?

Sebastian Wittnebel, MD PhD, Philippe Lewalle, MD PhD, Sandra Michiels, Soumaya Anoun, MD, Benjamin Bailly, MD, Marie Vercruyssen, MD, Julie Dallemagne, MD, Sarah Buntinx, MD, Phuong Huynh, MD, Patrick Crombez, Marie France Jaivenois, Dominique Bron, MD PhD

Blood (2015) 126 (23): 5454.

https://doi.org/10.1182/blood.V126.23.5454.5454

Published: 2015

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Prognostic Value of Neuro-Psychological and Biological Factors in Clinically Fit Older Patients with Hematological Malignancies

Stéphanie Dubruille, M.A., Yves Libert, PhD, Marie Maerevoet, MD, Myriam Roos, Aurélie Collard, Sandrine Vandenbossche, M.A., Nathalie Meuleman, MD PhD, Darius Razavi, MD PhD, Dominique Bron, MD PhD

Blood (2014) 124 (21): 2630.

https://doi.org/10.1182/blood.V124.21.2630.2630

Published: 2014

Journal Articles

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

Blood (2013) 122 (21): 86.

https://doi.org/10.1182/blood.V122.21.86.86

Published: 2013

Journal Articles

Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma

Martin Dreyling, Franck Morschhauser, MD, PhD, Dominique Bron, MD, PhD, Krimo Bouabdallah, MD, Umberto Vitolo, MD, Kim Linton, Eric Van Den Neste, MD, PhD, Silvia Mappa, MD, Marius Giurescu, MD, PhD, Barrett H. Childs, MD, Pier Luigi Zinzani, MD

Blood (2013) 122 (21): 87.

https://doi.org/10.1182/blood.V122.21.87.87

Published: 2013

Journal Articles

Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group

Blood (2013) 122 (21): 495.

https://doi.org/10.1182/blood.V122.21.495.495

Published: 2013

Journal Articles

Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05

Vincent Ribrag, MD, Herve Tilly, MD, Olivier Casasnovas, MD, Andre Bosly, MD, Reda Bouabdallah, MD, Richard Delarue, Francois Boue, MD, PhD, Dominique Bron, MD, PhD, Pierre Feugier, MD, PhD, Corinne Haioun, MD, Fritz C Offner, MD, PhD, Bertrand Coiffier, MD, PhD

Blood (2010) 116 (21): 768.

https://doi.org/10.1182/blood.V116.21.768.768

Published: 2010

Journal Articles

Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Single Centre Experience.

Marie Christine Ngirabacu, MD, John Kwan, MD, Rita Leroy, Phuong Huynh, MD, Dominique Bron, MD, PhD

Blood (2007) 110 (11): 1669.

https://doi.org/10.1182/blood.V110.11.1669.1669

Published: 2007

Journal Articles

Preemptive Management of Epstein-Barr Virus Reactivation after Hematopoietic Stem Cell Transplantation.

Imran Ahmad, MD, John Kwan, MD, Nathalie Meuleman, MD, Philippe Lewalle, MD, Francoise Crokaert, MD, PhD, Dominique Bron, MD, PhD

Blood (2007) 110 (11): 5000.

https://doi.org/10.1182/blood.V110.11.5000.5000

Published: 2007

Journal Articles

Laparoscopic Splenectomy for Hematologic Disorders: A Safe Procedure.

Christophe Ghys, MD, Elie Capelluto, MD, A. Baize, MS, Nathalie Meuleman, MD, Jalil Bennani, MD, Marc Libertalis, MD, Guy Bernard Cadiere, MD,PhD, Dominique Bron, MD,PhD

Blood (2006) 108 (11): 5523.

https://doi.org/10.1182/blood.V108.11.5523.5523

Published: 2006

Journal Articles

Ex Vivo Proliferation and Differentiation of CD34 + Cells into Myeloid Progenitor Cells: Cord Blood Versus Mobilized Peripheral Blood.

Cecile De Bruyn, PhD, Alain Delforge, PhD, Marie-Christine Ngirabacu, MD, Dominique Bron, MD, PhD

Blood (2006) 108 (11): 4175.

https://doi.org/10.1182/blood.V108.11.4175.4175

Published: 2006

NARROW

Cognitive Impairment, Hypoalbuminemia, High CRP Level and Past History of Gastro-Intestinal Ulcer: 4 Markers of Frailty Which Identify Older Patients with Malignant Hemopathies Who Shouldn't Benefit from Chemotherapy

Early Discontinuation of Lenalidomide in Patients with Relapsing or Refractory Multiple Myeloma: Predictive Factors for Stopping in the Real Life

Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?

Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Use of CD 123 Expression on Blasts from AML, ALL and RAEB As Minimal Residual Disease Marker

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

Long-Term Overall and Event-Free Survival after RIC Allogeneic Transplantation in Acute Leukemias in a Single Centre - Impact of Age and Donor Type?

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Prognostic Value of Neuro-Psychological and Biological Factors in Clinically Fit Older Patients with Hematological Malignancies

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma

Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group

Final Results of a Randomized Phase 2 Multicenter Study of Two Bortezomib Schedules In Patients with Recurrent or Refractory Follicular Lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study FL-05

Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Single Centre Experience.

Preemptive Management of Epstein-Barr Virus Reactivation after Hematopoietic Stem Cell Transplantation.

Laparoscopic Splenectomy for Hematologic Disorders: A Safe Procedure.

Ex Vivo Proliferation and Differentiation of CD34 + Cells into Myeloid Progenitor Cells: Cord Blood Versus Mobilized Peripheral Blood.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only